A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.

BACKGROUND: An oral formulation of fludarabine was introduced for use in chronic lymphocytic leukemia in 2001 following studies demonstrating the bioequivalence of a 40 mg/m(2) oral dose with a 25 mg/m(2) intravenous dose. We assessed retrospectively the efficacy of these two routes of administrati...

Full description

Bibliographic Details
Main Authors: Dearden, C, Richards, S, Else, M, Catovsky, D, Hillmen, P
Format: Journal article
Language:English
Published: 2011